Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Operating Leases: 2019-2024

Historic Operating Leases for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $148.0 million.

  • Beam Therapeutics' Operating Leases fell 6.97% to $138.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.7 million, marking a year-over-year decrease of 6.97%. This contributed to the annual value of $148.0 million for FY2024, which is 7.48% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Operating Leases is $148.0 million, which was down 7.48% from $159.9 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Operating Leases ranged from a high of $168.6 million in FY2022 and a low of $96.0 million during FY2020.
  • Moreover, its 3-year median value for Operating Leases was $159.9 million (2023), whereas its average is $158.8 million.
  • In the last 5 years, Beam Therapeutics' Operating Leases skyrocketed by 353.17% in 2020 and then fell by 7.48% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Operating Leases stood at $96.0 million in 2020, then surged by 40.41% to $134.8 million in 2021, then rose by 25.08% to $168.6 million in 2022, then declined by 5.17% to $159.9 million in 2023, then dropped by 7.48% to $148.0 million in 2024.